NGM Biopharmaceuticals Book Value 2011-2026 | NGM

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value NGM Biopharmaceuticals

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
149 M	260 M	336 M	280 M	331 M	187 M	-121 M	-115 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
336 M	-121 M	163 M

Quarterly Book Value NGM Biopharmaceuticals

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
170 M	192 M	221 M	260 M	286 M	-	311 M	336 M	354 M	373 M	400 M	280 M	280 M	280 M	280 M	331 M	331 M	331 M	331 M	187 M	187 M	187 M	187 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
400 M	170 M	277 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
ADC Therapeutics SA ADCT	88.7 M	$ 3.78	-	$ 105 M	Schweiz
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Akebia Therapeutics AKBA	32.6 M	$ 1.35	-2.17 %	$ 347 M	USA
Akari Therapeutics, Plc AKTX	28.3 M	$ 3.5	-21.7 %	$ 236 B	Britain
Aldeyra Therapeutics ALDX	44.3 M	$ 1.58	-4.82 %	$ 94.9 M	USA
Aligos Therapeutics ALGS	53.5 M	$ 8.36	4.89 %	$ 82.6 M	USA
Alnylam Pharmaceuticals ALNY	789 M	$ 330.71	3.72 %	$ 43.3 B	USA
Altimmune ALT	225 M	$ 3.47	3.89 %	$ 306 M	USA
ALX Oncology Holdings ALXO	26 M	$ 1.98	0.25 %	$ 106 M	USA
Amgen AMGN	90.6 B	$ 346.45	-0.43 %	$ 186 B	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Amneal Pharmaceuticals AMRX	3.68 B	$ 12.37	-0.92 %	$ 3.88 B	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Anika Therapeutics ANIK	271 M	$ 15.0	1.32 %	$ 220 M	USA
ANI Pharmaceuticals ANIP	429 M	$ 76.34	2.87 %	$ 1.47 B	USA
Annexon ANNX	212 M	$ 5.64	2.45 %	$ 875 M	USA
Aptorum Group Limited APM	11.8 M	$ 0.92	-1.11 %	$ 5.02 M	China
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Aprea Therapeutics APRE	15.9 M	$ 0.73	2.63 %	$ 4.77 M	USA
Aquestive Therapeutics AQST	-33.7 M	$ 4.15	0.48 %	$ 444 M	USA
Arcturus Therapeutics Holdings ARCT	214 M	$ 8.43	4.98 %	$ 231 M	Israel
Ardelyx ARDX	167 M	$ 6.08	2.27 %	$ 1.47 B	USA
argenx SE ARGX	7.32 B	$ 752.05	0.75 %	$ 25 B	Niderland
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Arcutis Biotherapeutics ARQT	189 M	$ 23.93	1.27 %	$ 3.04 B	USA
Arvinas ARVN	434 M	$ 11.11	2.4 %	$ 788 M	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Arrowhead Pharmaceuticals ARWR	1.39 B	$ 61.57	0.88 %	$ 8.24 B	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Assembly Biosciences ASMB	207 M	$ 30.01	3.43 %	$ 336 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Actinium Pharmaceuticals ATNM	7.83 M	$ 1.14	16.28 %	$ 35.6 M	USA
Atossa Therapeutics ATOS	39.4 M	$ 5.21	-2.89 %	$ 44.9 M	USA
Atara Biotherapeutics ATRA	-38.5 M	$ 5.03	0.7 %	$ 63.1 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Aurinia Pharmaceuticals AUPH	581 M	$ 16.04	2.75 %	$ 2.16 B	Canada
Autolus Therapeutics plc AUTL	178 M	$ 1.42	0.35 %	$ 378 M	Britain
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA